|
Alpelisib Clinical Trials
9 actively recruiting trials across 6 locations
Also known as: BYL 719, BYL-719, BYL719, PI3K Inhibitor, PIQRAY® +3 more
Pipeline
Phase 1: 2Phase 2: 4Phase 1/2: 2Phase 2/3: 1
Top Sponsors
- The Netherlands Cancer Institute1
- Stemline Therapeutics, Inc.1
- Olema Pharmaceuticals, Inc.1
- Novartis Pharmaceuticals1
- National Cancer Institute (NCI)1
Indications
- Cancer9
- Breast Cancer5
- Metastatic Breast Cancer2
- Unresectable HER2-Negative Breast Carcinoma1
- Arteriovenous Malformation (AVM)1
Other3 trials
Birmingham, Alabama1 trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
University of Alabama at Birmingham Cancer Center
Phase 2
Dothan, Alabama1 trial
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Dothan Hematology and Oncology
Phase 1/2
Gilbert, Arizona1 trial
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Banner MD Anderson Cancer Center
Phase 1
Oakland, California1 trial
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
UCSF Benioff Children s Hospital
Phase 2/3
Aurora, Colorado1 trial
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
University of Colorado Cancer Center
Phase 1/2
Lebanon, New Hampshire1 trial
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
Dartmouth Hitchcock Medical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.